This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas | MicrobiomeTrials
← Back to trials NCT07813884
Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-01Est. Completion: 2027-10-01
Enrollment target: 15 participantsLocations CHU de Nice, Nice, France Other microbiome trials you might be interested in Metastatic Colorectal Adenocarcinoma Recurrent Colorectal Adenocarcinoma Refractory Colorectal Adenocarcinoma Stage IV Colorectal Cancer AJCC v8
This phase I trial tests the safety, best dose, and effectiveness of ZEN003694 in combination with cetuximab and encoraf…
Costa Mesa, United States Est. completion Jan 30, 2027
Colorectal Neoplasms Neoplasms Intrahepatic Cholangiocarcinoma Adrenocortical Carcinoma Metastasis, Neoplasm
Background:
Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors …
Bethesda, United States Est. completion Dec 31, 2029